Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

Share Price is delayed by 15 minutes
Get Live Data
0.546    -0.034 (-5.86%)
Bid:
0.55
Ask:
0.60
Spread: 0.05 (9.091%)
Market Cap: £3.17m
FUM Live PriceLast checked at - London Stock Exchange

Intraday Futura Medical Share Chart

AGM Statement

24 Jun 2019 16:42

RNS Number : 2473D
Futura Medical PLC
24 June 2019
 

Results of Annual General Meeting

24 June 2019

Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys® drug delivery technology currently focused on sexual health and pain, announces that at its Annual General Meeting, held earlier today, all resolutions were duly passed by the shareholders.

 

For further information please contact:

Futura Medical plc James Barder, Chief ExecutiveAngela Hildreth, Finance Director and COO

Email: Investor.relations@futuramedical.comTel: +44 (0) 1483 685 670

Nominated Adviser and Sole Broker:LiberumBidhi Bhoma/ Euan Brown/ Kane CollingsTel: +44 (0) 203 100 2000

 

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 950 9144

 

Notes to editors:

 

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

 

The first European Phase 3 study for MED2005, referred to as "FM57", is a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study of MED2005 0.2%, 0.4% and 0.6% Glyceryl Trinitrate for the treatment of erectile dysfunction with an open label extension. FM57 is progressing on track, with headline data expected by the end of 2019.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGCKQDNPBKDFAB
Date   Source Headline
11th Jan 201712:20 pmRNSDirector's Dealings
10th Jan 201712:40 pmRNSNED Remuneration and Total Voting Rights
10th Jan 20177:00 amRNSSigns UK Licensing Agreement in Pain Relief
5th Jan 20177:00 amRNSInitial Launch of CSD500 in MENA
28th Nov 20165:30 pmRNSCorrection: Notification of Major Interests
28th Nov 201612:00 pmRNSNotification of Major Interest in Shares
25th Nov 20165:25 pmRNSCorrection - Block Listing Update
25th Nov 20163:05 pmRNSBlock Listing Update
25th Nov 20169:30 amRNSNotification Of Major Interest In Shares
23rd Nov 20163:30 pmRNSNotification of Major Interest in Shares
16th Nov 20167:00 amRNSKen James to lead Futura's R&D
16th Nov 20167:00 amRNSMED2002 Update
15th Nov 20163:38 pmRNSResult of General Meeting
27th Oct 201612:45 pmRNSResult of Placing
27th Oct 20169:48 amRNSClose of Accelerated Bookbuild
27th Oct 20167:01 amRNSProposed Accelerated Bookbuild
27th Oct 20167:00 amRNSCSD500: Approval of TTK with Extended Shelf Life
13th Sep 20167:00 amRNSInterim Results
12th Sep 20165:45 pmRNSNotification of Major Interest in Shares
12th Sep 20163:00 pmRNSNotification of Major Interest in Shares
7th Sep 20167:00 amRNSMED2002: Breakthrough Results in $5 billion Market
25th Jul 20167:00 amRNSNotification of Half Year Results
21st Jun 20165:30 pmRNSResult of AGM
21st Jun 20167:00 amRNSAGM Statement
20th Jun 20167:00 amRNSLicenses CSD500 to Milsing for Southeast Europe
13th Jun 20167:00 amRNSManufacturing and Distribution Agreements with TTK
19th May 20164:30 pmRNSBlock Listing Update
4th May 20167:00 amRNSRecruitment Closes in MED2002 Study
26th Apr 201611:39 amRNSNotice of AGM
15th Mar 20167:00 amRNSPreliminary Results
7th Mar 20167:00 amRNSAppointment of Non-Executive Director
26th Feb 201612:00 pmRNSNotification of Major Interest in Shares
26th Jan 20167:00 amRNSCapital Markets Event
20th Jan 20167:00 amRNSCapital Markets Event
18th Jan 20162:33 pmRNSNotice of Preliminary Results
4th Jan 20161:15 pmRNSRemuneration of Non-Executive Directors
16th Dec 20157:00 amRNSExtends Shelf Life of CSD500
1st Dec 201510:13 amRNSNotification of Major Interest in Shares
24th Nov 20157:00 amRNSPositive Regulatory Update on Pain Portfolio
23rd Nov 20153:42 pmRNSBlocklisting Interim Review
23rd Nov 20153:18 pmRNSBlock Listing Update
17th Nov 20157:00 amRNSMED2002 Clinical Trial Update
23rd Oct 20157:00 amRNSNHS Reimbursement for MED2002 as a Special
14th Oct 20157:00 amRNSLicensing Agreement for MED2002
9th Oct 20157:30 amRNSNotification of Major Interest in Shares
10th Sep 20157:00 amRNSGrant of Options
9th Sep 20157:00 amRNSInterim Results
19th Aug 20153:15 pmRNSNotification of Major Interest in Shares
19th Aug 20157:00 amRNSNotice of Interim Results
16th Jul 20154:23 pmRNSNotification of Major Interest in Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.